Related Experiment Videos
Magnesium pyridoxal 5-phosphate glutamate reduces hyperlipidaemia in patients with chronic renal insufficiency
Insights
Magnesium pyridoxal 5-phosphate glutamate (MPPG) effectively lowered cholesterol and triglycerides in patients with chronic renal insufficiency. This study found MPPG to be a safe and effective antihyperlipidaemic agent for this patient group.
Area of Science:
- Nephrology
- Cardiology
- Biochemistry
Background:
- Chronic renal insufficiency frequently co-occurs with hyperlipidemia, increasing the risk of coronary heart disease.
- Managing lipid profiles in patients with kidney disease is crucial for cardiovascular health.
Purpose of the Study:
- To evaluate the efficacy of magnesium pyridoxal 5-phosphate glutamate (MPPG) as an antihyperlipidaemic agent in patients with chronic renal insufficiency.
- To assess the safety and side effect profile of MPPG in this specific patient population.
Main Methods:
- A double-blind, randomized study involving 30 patients with serum creatinine > 2 mg/100 ml and serum cholesterol < 250 mg/100 ml.
- Patients were assigned to receive either 150 mg of MPPG daily or a placebo for 12 weeks.
- Lipid profiles, including total cholesterol, triglycerides, and LDL/HDL ratio, were monitored.
Main Results:
- MPPG treatment resulted in significantly lower total cholesterol levels compared to placebo (282.4 mg/100 ml vs. 354.3 mg/100 ml).
- Triglyceride levels were also reduced in the MPPG group (265.1 mg/100 ml vs. 361.9 mg/100 ml).
- The LDL/HDL ratio decreased from 6.83 in the placebo group to 3.56 in the MPPG group after 12 weeks.
Conclusions:
- MPPG demonstrated significant antihyperlipidaemic effects in patients suffering from renal insufficiency.
- The side effect profile of MPPG was comparable to placebo, suggesting good tolerability.
- MPPG represents a promising therapeutic option for managing dyslipidemia in patients with chronic kidney disease.
Abstract:
Chronic renal insufficiency is often accompanied by hyperlipidaemia and subsequent coronary heart disease. Two groups of 15 patients with serum creatinine greater than 2 mg/100 ml and serum cholesterol less than 250 mg/100 ml were given 3 x 50 mg magnesium pyridoxal 5-phosphate glutamate (MPPG) or placebo for 12 weeks in a double-blind, randomised study. Total cholesterol in the MPPG group (282.4 mg.100 ml-1) was lower than in the placebo group (354.3 mg.100 ml-1) after 12 weeks of treatment. Triglycerides in the MPPG group were 265.1 mg.100 ml-1 compared to 361.9 mg.100 ml-1. After 12 weeks on MPPG the LDL/HDL ratio of 3.56 was lower than in the placebo group-6.83. Side effects in the MPPG group were similar to those in the placebo group. Thus, MPPG was an effective antihyperlipidaemic agent in patients with renal insufficiency.